BiotechTube

ASP3082

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic/Locally Advanced Non-Small-Cell Lung Cancer

Conditions

Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma

Trial Timeline

Mar 1, 2026 → Oct 1, 2027

NCT ID
NCT07483983

About ASP3082

ASP3082 is a phase 2 stage product being developed by Astellas Pharma for Metastatic/Locally Advanced Non-Small-Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07483983. Target conditions include Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07483983Phase 2Recruiting

Competing Products

1 competing product in Metastatic/Locally Advanced Non-Small-Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
TarlatamabAmgenPhase 2
51

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85